Current concepts in systemic and topical therapy for superficial mycoses

Abstract There presently exists a wide selection of choices in the treatment of superficial mycoses. The main categories of broad-spectrum agents are the allylamines and imidazoles, which have been tried and proven over more than 2 decades of usage with good safety. Nystatin and griseofulvin have ev...

Full description

Saved in:
Bibliographic Details
Published in:Clinics in dermatology 2010-03, Vol.28 (2), p.212-216
Main Author: Millikan, Larry E., MD
Format: Article
Language:English
Subjects:
Administration, Oral
Administration, Topical
Anti-Bacterial Agents - therapeutic use
Antifungal Agents - economics
Antifungal Agents - therapeutic use
Azoles - economics
Azoles - therapeutic use
Dermatology
Dermatomycoses - drug therapy
Dermatomycoses - economics
Dermatomycoses - epidemiology
Drug Administration Schedule
Drug Resistance, Fungal - drug effects
Fluconazole - therapeutic use
Griseofulvin - therapeutic use
Humans
Itraconazole - therapeutic use
Ketoconazole - therapeutic use
Morpholines - therapeutic use
Tolnaftate - therapeutic use
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract There presently exists a wide selection of choices in the treatment of superficial mycoses. The main categories of broad-spectrum agents are the allylamines and imidazoles, which have been tried and proven over more than 2 decades of usage with good safety. Nystatin and griseofulvin have even longer experience of about 5 decades but have niche usage for yeasts and dermatophytes, respectively. Although no new therapeutic groups have appeared, extensive development of vehicles and delivery systems has enhanced therapeutic results and increased patient compliance.
ISSN:0738-081X
1879-1131
DOI:10.1016/j.clindermatol.2009.12.016